Tert-butyl 4-(5-formylfuran-2-yl)piperazine-1-carboxylate | 1219911-62-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: Tert-butyl 4-(5-formylfuran-2-yl)piperazine-1-carboxylate
• CAS: 1219911-62-2
• 化学式: C₁₄H₂₀N₂O₄
• 分子量: 280.32
• InChiKey: FNNOEZIWGHIYEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  63
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Methods for using 5-HMF analogs with increased solubility to inhibit or reverse RBC sickling
  申请人：King Abdulaziz University

  公开号：US11458144B1

  公开（公告）日：2022-10-04

  Methods for administering compounds provide a rapid treatment for sickle cell disease (SCD) to inhibit or reverse red blood cell sickling. The compounds are a group of 5-hydroxymethylfurfural (5-HMF) analogs modified to increase water-solubility. The compounds can be formulated in an aqueous carrier and administered intravenously for immediate uptake into red blood cells (RBCs) within hours, rather than days or weeks. In vitro experiments demonstrated rapid uptake into RBCs and increased O2 affinity of HbS to an equilibrium point within 30 to 90 minutes. The compounds have a desired level of safety as well as a short half-life, both of which are compatible with acute usage. Thus, the methods of treatment rapidly achieve therapeutic steady-state drug levels, making it possible to deliver a treatment in critical emergency care situations to prevent, reverse and otherwise treat acute sickling or anemia.

  施用化合物的方法可快速治疗镰状细胞病（SCD），抑制或逆转红细胞镰状化。这些化合物是一组 5-hydroxymethylfurfural (5-HMF) 类似物，经过改良后可提高水溶性。这些化合物可配制在水性载体中，通过静脉注射在数小时内而不是数天或数周内立即被红细胞吸收。体外实验表明，HbS 能迅速被红细胞吸收，并在 30 至 90 分钟内将 HbS 的氧气亲和力提高到平衡点。这些化合物具有理想的安全性和较短的半衰期，两者都适合急性使用。因此，治疗方法可迅速达到治疗稳态药物水平，从而有可能在危急的紧急护理情况下提供治疗，以预防、逆转和治疗急性镰状红细胞症或贫血症。